Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A study has shown that two compounds being developed by Allon Therapeutics, have the potential to protect and repair cells of the brain and central nervous system from disease or injury.
Subscribe to our email newsletter
The two proprietary compounds are NAP, from which Allon has derived its first and second products AL-108 and AL-208, and ADNF-9, from which the company has derived product candidates now undergoing preclinical studies. AL-108 is being evaluated in phase I human clinical trials as a treatment for Alzheimer’s disease. AL-208 is being evaluated in phase I human clinical trials as a treatment for mild cognitive impairment (MCI) associated with coronary artery bypass graft (CABG) surgery.
Professor Illana Gozes, chief scientific officer of Allon, said, “The study further explains the neuroprotective mechanism of action of Allon’s compounds. The study adds to our extensive body of preclinical research confirming the potential of our compounds to protect against and treat a number of neurodegenerative diseases and conditions.”
The study, published in the August 2005 issue of the Journal of Neuroscience, demonstrated that NAP and ADNF-9 both activate PARP-1, a protein shown in several other studies to have a protective effect on neurons.